AG0301-COVID19
AG0301-COVID19 Uses, Dosage, Side Effects, Food Interaction and all others data.
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product. On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).
Trade Name | AG0301-COVID19 |
Generic | AG0301-COVID19 |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here AG0301-COVID19